FR17C1058I1 - - Google Patents

Info

Publication number
FR17C1058I1
FR17C1058I1 FR17C1058C FR17C1058I1 FR 17C1058 I1 FR17C1058 I1 FR 17C1058I1 FR 17C1058 C FR17C1058 C FR 17C1058C FR 17C1058 I1 FR17C1058 I1 FR 17C1058I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04760321A external-priority patent/EP1617832B1/fr
Application filed filed Critical
Publication of FR17C1058I1 publication Critical patent/FR17C1058I1/fr
Application granted granted Critical
Publication of FR17C1058I2 publication Critical patent/FR17C1058I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR17C1058C 2003-04-29 2017-12-08 Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids Active FR17C1058I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46683803P 2003-04-29 2003-04-29
EP04760321A EP1617832B1 (fr) 2003-04-29 2004-04-21 Compositions influant sur la perte de poids
EP07116330A EP1870096A3 (fr) 2003-04-29 2004-04-21 Compositions pour influencer la perte de poids

Publications (2)

Publication Number Publication Date
FR17C1058I1 true FR17C1058I1 (fr) 2018-01-12
FR17C1058I2 FR17C1058I2 (fr) 2019-01-11

Family

ID=38719840

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1058C Active FR17C1058I2 (fr) 2003-04-29 2017-12-08 Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids

Country Status (6)

Country Link
EP (1) EP1870096A3 (fr)
BE (1) BE2017C064I2 (fr)
CY (2) CY1119418T1 (fr)
FR (1) FR17C1058I2 (fr)
LU (1) LUC00054I2 (fr)
NL (1) NL300918I2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576045B2 (en) 2011-02-16 2020-03-03 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
EP2950799B1 (fr) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Traitement de la dépression et autres maladies avec un agent à faible dose

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
DK0782445T3 (da) * 1994-09-19 2002-05-06 Bristol Myers Squibb Pharma Co Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed
ES2393303T3 (es) * 1996-05-07 2012-12-20 Veroscience Llc Uso médico y composición para el tratamiento de trastornos del metabolismo de lípidos y de glucosa
WO1999038504A1 (fr) * 1998-01-29 1999-08-05 Sepracor Inc. Utilisations pharmaceutiques de (-)-bupropion optiquement pur
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2001052851A1 (fr) * 2000-01-22 2001-07-26 Albert Shulman Methodes de traitement d'abus de substances
WO2002022151A2 (fr) * 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Utilisation de peptides glp-1 et glp-2
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
KR101108014B1 (ko) * 2002-05-17 2012-01-25 티오가 파마슈티칼스, 인코포레이티드 선택성 아편제 수용체 조절인자로서 효과적인 화합물의 용도
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake

Also Published As

Publication number Publication date
CY2017041I1 (el) 2018-09-05
EP1870096A2 (fr) 2007-12-26
EP1870096A3 (fr) 2011-04-20
BE2017C064I2 (fr) 2023-08-09
LUC00054I1 (fr) 2017-12-13
CY2017041I2 (el) 2018-09-05
CY1119418T1 (el) 2018-03-07
FR17C1058I2 (fr) 2019-01-11
NL300918I2 (nl) 2018-01-09
LUC00054I2 (fr) 2018-02-21
NL300918I1 (nl) 2017-12-14

Similar Documents

Publication Publication Date Title
BE2015C007I2 (fr)
BE2014C055I2 (fr)
BE2014C027I2 (fr)
BE2014C003I2 (fr)
BE2013C075I2 (fr)
BE2013C069I2 (fr)
BE2013C067I2 (fr)
BE2013C038I2 (fr)
BE2013C036I2 (fr)
BE2011C030I2 (fr)
JP2004202226A5 (fr)
JP2004030586A5 (fr)
JP2003326928A5 (fr)
JP2004176723A5 (fr)
JP2004005694A5 (fr)
JP2004047954A5 (fr)
BE2015C005I2 (fr)
JP2004007424A5 (fr)
JP2004002812A5 (fr)
JP2004227097A5 (fr)
JP2004219126A5 (fr)
LUC00054I1 (fr)
JP2004145285A5 (fr)
JP2003336592A5 (fr)
AU2002256398A1 (fr)